This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Updated Feb. 8, 2022 8:26 am ET / Original Feb. 7, 2022 10:09 am ET
- Order Reprints
- Print Article
Pfizer now expects approximately $55 billion in combined revenues for its Covid-19 vaccine and antiviral in 2022, and what would be a record high overall revenue of between $98 billion and $102 billion.
Pfizer (ticker: PFE) reported full-year 2021 revenue of $81.3 billion early Tuesday, roughly in line with the FactSet consensus estimate of $81.8 billion, and full-year adjusted diluted earnings of $4.42 per share, above the FactSet consensus estimate of $4.41 per share.